Moderna Stock News

Here is a look at 10 top tech stocks that were making the biggest moves shortly after Tuesday''s opening bell.

Will Moderna’s Omicron-specific vaccine bolster their stock outlook? See why despite the stock falling since their August peak, we are upgrading our rating to a buy.

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

The mRNA COVID-19 vaccines from Pfizer and Moderna have proved remarkably effective at providing protection from the coronavirus.

CDC Signals Changes To COVID Vaccine Schedule, In Part To Address Heart Inflammation Authored by Zachary Stieber via The Epoch Times, The Centers for Disease Control and Prevention (CDC) on Feb. 4 outlined an expected change to the COVID-19 vaccine schedule for people with weak immune systems and signaled that a different alteration is coming for the general population to try to cut the number of post-vaccination heart inflammation cases . The CDC told its vaccine advisory panel that its planning to adjust guidance for people with compromised immune systems, a group that doesnt respond as well to vaccines as the general population and is the only population that is advised to get four doses of the Moderna or Pfizer messenger RNA (mRNA) vaccines. Current CDC guidance for the immunocompromised says they should receive three doses of an mRNA vaccine within two months, and a fourth dose at least five months after the third dose. The revised schedule would recommend the population get that fourth shot as soon as three months after their third one.

Over the past three months, shares of Plains All American (NASDAQ: PAA ) moved higher by 11.86%. Before having a look at the importance of debt, let us look at how much debt Plains All American has. Plains All American''s Debt According to the Plains All American''s most recent financial statement as reported on November 8, 2021, total debt is at $9.20 billion, with $8.39 billion in long-term debt and $808.00 million in current debt. Adjusting for $191.00 million in cash-equivalents, the company has a net debt of $9.01 billion. Also check out this: Moderna And 4 Other Stocks Sold By Insiders Let''s define some of the terms we used in the paragraph above. Current debt is … Full story available on Benzinga.com

Over the past three months, shares of NGL Energy Partners (NYSE: NGL ) rose by 10.18%. Before we understand the importance of debt, let us look at how much debt NGL Energy Partners has. Also check out this: Moderna And 4 Other Stocks Sold By Insiders NGL Energy Partners''s Debt According to the NGL Energy Partners''s most recent balance sheet as reported on November 9, 2021, total debt is at $3.42 billion, with $3.42 billion in long-term debt and $2.28 million in current debt. Adjusting for $5.53 million in cash-equivalents, the company has a net debt of $3.42 billion. Let''s define some of the terms we used in the paragraph above. Current debt is the portion of … Full story available on Benzinga.com

In the current market session, Fox Inc. (NASDAQ: FOXA ) is trading at $40.66, after a 0.09% decrease. However, over the past month, the stock increased by 4.36%, and in the past year, by 32.28%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. Also check out this: Moderna And 4 Other Stocks Sold By Insiders Assuming that all other factors are held constant, this could present itself as an opportunity Full story available on Benzinga.com

Right now, Yum Brands Inc. (NYSE: YUM ) share price is at $125.88, after a 0.49% increase. Moreover, over the past month, the stock fell by 3.68% , but in the past year, went up by 22.05% . Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. Also check out this: Moderna And 4 Other Stocks Sold By Insiders Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders … Full story available on Benzinga.com

Moderna stock yo-yoed Monday after a new U.S. study suggested its omicron-specific booster might not be necessary.

Callable Multi Barrier Reverse Convertible auf BioNTech, Johnson & Johnson, Merck, Moderna, Pfizer / Idorsia, Lonza, Novartis, Roche, Zur Rose Group AG

The Food and Drug Administration (FDA) has restored a document outlining why it approved Modernas COVID-19 vaccine, days after the regulatory agency pulled the 30-page file offline after receiving questions about it from The Epoch Times. No explanation has been given for why the document vanished hours after the questions were sent, but the removal []

About half the countrys population is yet to receive a single dose of vaccine, despite availability Coronavirus latest updates See all our coronavirus coverage In a vaccination centre in El Alto, Bolivia, the staff bagged up in protective gear far outnumbered the few people sitting in plastic chairs waiting for their injection. A young doctor reeled off a list of all the vaccines available: Sinopharm, Sputnik, Pfizer, Moderna. Whats lacking is demand. They see 100 people on a good day. South America, once the region most afflicted by the pandemic, is now the most vaccinated in the world. But this turnaround doesnt extend to Bolivia, where roughly half the population is yet to receive a single dose even though the state has had all the vaccines it needs since October. Continue reading

South African biotechnology company Afrigen Biologics has used publicly available data on Moderna''s mRNA vaccine to produce a vaccine of its own at a Cape Town facility.The vaccine could be tested in humans by the end of the year, Afrigen''…

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices met Friday to discuss potential implications of both Pfizer and Modernas shots.